Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2beta-Thalassemia 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
luspatercept × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡